Clinical, pathological and molecular characteristics of colorectal cancer cases according to CD14+ cell and CD15+ cell densities
| Characteristic* | All cases (N=913) | Overall CD14+ cell density | Overall CD15+ cell density | ||||||
| Q1 (lowest) (N=228) | Q2 (N=228) | Q3 (N=229) | Q4 (highest) (N=228) | Q1 (lowest) (N=228) | Q2 (N=228) | Q3 (N=229) | Q4 (highest) (N=228) | ||
| Sex, n (%) | |||||||||
| Female (NHS) | 505 (55) | 128 (56) | 131 (57) | 121 (53) | 125 (55) | 122 (54) | 119 (52) | 135 (59) | 129 (57) |
| Male (HPFS) | 408 (45) | 100 (44) | 97 (43) | 108 (47) | 103 (45) | 106 (46) | 109 (48) | 94 (41) | 99 (43) |
| Mean age±SD (years) | 68.8±8.9 | 68.2±8.8 | 69.0±8.7 | 68.6±9.1 | 69.7±8.9 | 67.7±9.3 | 69.2±8.7 | 68.9±8.9 | 69.6±8.7 |
| Year of diagnosis, n (%) | |||||||||
| 1995 or before | 301 (33) | 85 (37) | 72 (32) | 76 (33) | 68 (30) | 80 (35) | 74 (32) | 85 (37) | 62 (27) |
| 1996–2000 | 299 (33) | 72 (32) | 76 (33) | 76 (33) | 75 (33) | 75 (33) | 79 (35) | 72 (31) | 73 (32) |
| 2001–2008 | 313 (34) | 71 (31) | 80 (35) | 77 (34) | 85 (37) | 73 (32) | 75 (33) | 72 (31) | 93 (41) |
| Family history of colorectal cancer in first-degree relative(s), n (%) | |||||||||
| Absent | 720 (79) | 181 (80) | 183 (81) | 185 (81) | 171 (76) | 174 (77) | 184 (81) | 178 (78) | 184 (81) |
| Present | 189 (21) | 46 (20) | 44 (19) | 44 (19) | 55 (24) | 51 (23) | 43 (19) | 51 (22) | 44 (19) |
| Tumor location, n (%) | |||||||||
| Cecum | 159 (17) | 33 (15) | 31 (14) | 46 (20) | 49 (22) | 38 (17) | 32 (14) | 37 (16) | 52 (23) |
| Ascending to transverse colon | 298 (33) | 78 (34) | 75 (33) | 71 (31) | 74 (33) | 64 (28) | 79 (35) | 72 (32) | 83 (36) |
| Descending to sigmoid colon | 272 (30) | 71 (31) | 69 (30) | 69 (30) | 63 (28) | 82 (36) | 64 (28) | 75 (33) | 51 (22) |
| Rectum | 178 (20) | 45 (20) | 53 (23) | 41 (18) | 41 (18) | 42 (19) | 52 (23) | 44 (19) | 42 (18) |
| AJCC disease stage, n (%) | |||||||||
| I | 193 (23) | 44 (20) | 47 (22) | 52 (24) | 50 (24) | 40 (19) | 45 (21) | 55 (26) | 53 (24) |
| II | 283 (33) | 67 (31) | 65 (31) | 69 (32) | 82 (39) | 66 (31) | 71 (34) | 73 (35) | 73 (34) |
| III | 245 (29) | 66 (30) | 64 (30) | 59 (28) | 56 (27) | 64 (30) | 62 (30) | 54 (26) | 65 (30) |
| IV | 130 (15) | 41 (19) | 36 (17) | 33 (15) | 20 (9.6) | 43 (20) | 32 (15) | 29 (14) | 26 (12) |
| Tumor differentiation, n (%) | |||||||||
| Well to moderate | 824 (90) | 212 (93) | 215 (94) | 204 (89) | 193 (85) | 209 (92) | 212 (93) | 211 (92) | 192 (84) |
| Poor | 88 (9.7) | 15 (6.6) | 13 (5.7) | 25 (11) | 35 (15) | 18 (7.9) | 16 (7.0) | 18 (7.9) | 36 (16) |
| MSI status, n (%) | |||||||||
| Non-MSI-high | 735 (83) | 196 (87) | 190 (87) | 180 (81) | 169 (75) | 209 (94) | 194 (86) | 179 (82) | 153 (69) |
| MSI-high | 154 (17) | 29 (13) | 28 (13) | 42 (19) | 55 (25) | 14 (6.3) | 31 (14) | 39 (18) | 70 (31) |
| CIMP status, n (%) | |||||||||
| Low/negative | 686 (81) | 187 (87) | 188 (87) | 160 (77) | 151 (73) | 188 (90) | 181 (85) | 170 (81) | 147 (70) |
| High | 159 (19) | 29 (13) | 27 (13) | 48 (23) | 55 (27) | 22 (10) | 32 (15) | 41 (19) | 64 (30) |
| Mean LINE-1 methylation level±SD (%) | 62.5±9.5 | 61.5±9.6 | 61.6±9.7 | 62.5±9.5 | 64.5±9.1 | 61.1±9.8 | 61.5±9.5 | 62.8±9.6 | 64.8±8.9 |
| KRAS mutation, n (%) | |||||||||
| Wild-type | 530 (60) | 121 (54) | 134 (61) | 127 (57) | 148 (67) | 129 (58) | 128 (57) | 135 (62) | 138 (63) |
| Mutant | 356 (40) | 102 (46) | 87 (39) | 94 (43) | 73 (33) | 93 (42) | 98 (43) | 84 (38) | 81 (37) |
| BRAF mutation, n (%) | |||||||||
| Wild-type | 757 (85) | 192 (86) | 196 (87) | 181 (81) | 188 (85) | 194 (86) | 198 (89) | 192 (86) | 173 (78) |
| Mutant | 136 (15) | 32 (14) | 28 (13) | 43 (19) | 33 (15) | 31 (14) | 24 (11) | 31 (14) | 50 (22) |
| PIK3CA mutation, n (%) | |||||||||
| Wild-type | 698 (84) | 179 (84) | 173 (85) | 182 (86) | 164 (80) | 187 (89) | 171 (81) | 175 (86) | 165 (79) |
| Mutant | 136 (16) | 35 (16) | 30 (15) | 29 (14) | 42 (20) | 24 (11) | 41 (19) | 28 (14) | 43 (21) |
| Neoantigen load, n (%) | |||||||||
| Q1 (lowest) | 103 (25) | 30 (29) | 22 (21) | 25 (24) | 26 (25) | 28 (27) | 25 (24) | 29 (28) | 21 (20) |
| Q2 | 103 (25) | 29 (28) | 33 (32) | 23 (22) | 18 (17) | 30 (29) | 25 (24) | 24 (23) | 24 (23) |
| Q3 | 103 (25) | 23 (22) | 22 (21) | 32 (31) | 26 (25) | 27 (26) | 27 (26) | 22 (21) | 27 (26) |
| Q4 (highest) | 103 (25) | 21 (20) | 26 (25) | 23 (22) | 33 (32) | 18 (17) | 26 (25) | 28 (27) | 31 (30) |
*Percentage indicates the proportion of patients with a specific clinical, pathologic or molecular characteristic among all patients or in strata of myeloid cell density.
AJCC, American Joint Committee on Cancer; CIMP, CpG island methylator phenotype; HPFS, Health Professionals Follow-up Study; LINE-1, long-interspersed nucleotide element-1; MSI, microsatellite instability; NHS, Nurses’ Health Study.;